Adel Galal El-Shemi
Overview
Explore the profile of Adel Galal El-Shemi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hassanein R, El-Shemi A, Albalawi B
Pan Afr Med J
. 2023 Jul;
45:11.
PMID: 37426462
Introduction: cutaneous leishmaniasis (CL) is a vector-borne protozoan skin disease that affects all human ages and can pose extreme social and psychological impacts. This study aimed to reveal the epidemiological...
2.
Hassanein R, El-Shemi A, Alkurbi M, Alahmadi A, Almatery W
Pan Afr Med J
. 2022 Aug;
42:72.
PMID: 36034029
Introduction: toxoplasmosis is an opportunistic protozoan disease caused by Toxoplasma gondii (T. gondii) infection. It affects all human ages, including children, and can pose serious health problems, particularly in developing...
3.
Gonzalez-Pastor R, Ashshi A, El-Shemi A, Dmitriev I, Kashentseva E, Lu Z, et al.
J Ovarian Res
. 2019 Feb;
12(1):18.
PMID: 30767772
Background: Virotherapy represents a promising approach for ovarian cancer. In this regard, conditionally replicative adenovirus (CRAd) has been translated to the context of human clinical trials. Advanced design of CRAds...
4.
El-Shemi A, Kensara O, Alsaegh A, Hasan Mukhtar M
Pharmacology
. 2017 Sep;
101(1-2):9-21.
PMID: 28926842
Aims: This study is aimed at evaluating the antidiabetic effects of thymoquinone (TQ) on streptozotocin (STZ)-induced diabetes in rats, and exploring the possible underlying mechanisms. Methods: Diabetes was induced in...
5.
Refaat B, El-Shemi A, Mohamed A, Kensara O, Ahmad J, Idris S
BMC Cancer
. 2016 Nov;
16(1):879.
PMID: 27835986
Background: Activin-A may exert pro- or anti-tumorigenic activities depending on cellular context. However, little is known about its role, or the other mature activin proteins, in colorectal carcinoma (CRC). This...
6.
Kensara O, El-Shemi A, Mohamed A, Refaat B, Idris S, Ahmad J
Drug Des Devel Ther
. 2016 Jul;
10:2239-53.
PMID: 27468227
Colorectal cancer (CRC) is one of the most prevalent cancers and has a high mortality rate. Insensitivity and the limited therapeutic efficacy of its standard chemotherapeutic drug, 5-fluorouracil (5-FU), represents...
7.
Ashshi A, El-Shemi A, Dmitriev I, Kashentseva E, Curiel D
J Ovarian Res
. 2016 Jun;
9(1):38.
PMID: 27349517
Background: A major hurdle incurrent to the human clinical application of conditionally replicative adenovirus (CRAd)-based virotherapy agents is their limited therapeutic efficacy. In this study we evaluated whether arming our...
8.
El-Shemi A, Ashshi A, Na Y, Li Y, Basalamah M, Al-Allaf F, et al.
J Exp Clin Cancer Res
. 2016 Jun;
35(1):96.
PMID: 27316948
No abstract available.
9.
El-Shemi A, Ashshi A, Na Y, Li Y, Basalamah M, Al-Allaf F, et al.
J Exp Clin Cancer Res
. 2016 May;
35:74.
PMID: 27154307
Background: Gene-based virotherapy mediated by oncolytic viruses is currently experiencing a renaissance in cancer therapy. However, relatively little attention has been given to the potentiality of dual gene virotherapy strategy...
10.
El-Shemi A, Refaat B, Kensara O, Mohamed A, Idris S, Ahmad J
Cancer Prev Res (Phila)
. 2016 Mar;
9(6):491-501.
PMID: 27020656
Colorectal cancer is a common cancer with high mortality rate. Despite being the standard anti-colorectal cancer drug, 5-fluorouracil (5-FU) exhibits only limited therapeutic benefits. Herein, we investigated whether paricalcitol, a...